Continuous Subcutaneous Infusion Pumps in Parkinson’s Disease

A panelist discusses how recently FDA-approved subcutaneous infusion pumps represent a significant advancement in Parkinson disease management by offering continuous delivery of levodopa/carbidopa, which helps maintain stable plasma drug levels. This approach addresses the limitations of oral medications, such as fluctuating drug concentrations and “off” periods, by providing steady dopaminergic stimulation throughout the day. The continuous infusion method aims to reduce motor complications and improve overall symptom control for patients with advanced Parkinson disease.

The panelist highlights clinical data demonstrating that subcutaneous infusion pumps can significantly reduce motor fluctuations, including “off” time and dyskinesia, compared with standard oral therapies. These devices provide a more consistent therapeutic effect, which can translate to improved daily functioning and quality of life. Furthermore, the minimally invasive nature of subcutaneous administration offers a practical alternative to more invasive procedures, such as deep brain stimulation or intestinal gel infusions.

In clinical practice, the panelist notes that the availability of subcutaneous infusion pumps expands treatment options for patients with advanced Parkinson disease who experience significant motor fluctuations despite optimized oral therapy. While patient selection and education are crucial to maximize benefits and adherence, these pumps represent a promising tool to address unmet needs in PD care and enhance individualized treatment strategies.